29 Jul Testosterone Peptides: Which Ones Actually Raise Testosterone (and Which Don’t)

Do peptides actually raise testosterone?

Some can. Many do not.

The therapies most capable of increasing your own testosterone production are those that act directly on the hypothalamic-pituitary-gonadal, or HPG, axis. This is the signaling pathway connecting the brain, pituitary gland, and testes.

Gonadorelin acts near the top of this pathway by mimicking gonadotropin-releasing hormone (GnRH). Human chorionic gonadotropin, or HCG, acts farther downstream by mimicking luteinizing hormone (LH) at the testes. Kisspeptin acts even farther upstream, stimulating the reproductive signaling system that controls GnRH release, although its use as a testosterone therapy remains investigational.

Other popular peptides occupy different categories.

Sermorelin, CJC-1295, and ipamorelin target the growth hormone axis rather than the HPG axis. They should not be described as direct testosterone boosters.

Bremelanotide, or PT-141, targets pathways involved in sexual desire and arousal. It does not raise testosterone.

This distinction is more than academic. If a man has secondary hypogonadism, meaning the testes may still be capable of producing testosterone but are not receiving adequate hormonal stimulation, a treatment that restores or replaces that signal may be useful in selected cases. If the problem is primary testicular failure, simply sending more signals from the brain or pituitary may not solve it.

That is why choosing a therapy by its reputation online, rather than by the underlying physiology shown in your lab results, can lead to disappointing outcomes and unnecessary risk.

How testosterone peptides work: the HPG axis map

To understand which peptides can affect testosterone, it helps to understand the pathway that controls its production.

The HPG axis works roughly like this:

Hypothalamus → GnRH → Pituitary → LH and FSH → Testes → Testosterone and sperm production

The hypothalamus in the brain releases GnRH in pulses. GnRH then signals the pituitary gland to release LH and follicle-stimulating hormone, or FSH. LH primarily stimulates Leydig cells in the testes to produce testosterone, while FSH works with intratesticular testosterone to support sperm production.

GnRH signaling is naturally pulsatile rather than continuous, and the timing of those pulses is important to normal reproductive hormone signaling. [1] 

That pulsatility explains why treatments acting on this pathway cannot be understood simply as “more stimulation equals more testosterone.”

When GnRH receptors are stimulated appropriately and intermittently, the pituitary can release LH and FSH. With sustained exposure to certain long-acting GnRH, also called LHRH, agonists, however, the system eventually becomes desensitized and gonadotropin secretion falls.

The important exception: LHRH agonists can suppress testosterone

Leuprolide and triptorelin illustrate why the exact drug and mechanism matter.

These medications are GnRH/LHRH agonists, but they are not testosterone optimization therapies. They initially stimulate the pathway and can cause a temporary rise known as a testosterone flare. Continued exposure then suppresses pituitary signaling and substantially lowers testosterone production. [2] 

That suppressive effect is used therapeutically in conditions such as prostate cancer and other hormone-sensitive disorders. These are specialist-managed medications, not peptides to use for increasing testosterone.

The broader lesson is important: two therapies may interact with the same hormonal axis and produce very different outcomes depending on where, how, and for how long they act.

Peptides that can raise your testosterone directly through the HPG axis

If the goal is to stimulate endogenous testosterone production, the most relevant therapies are those that directly influence the HPG axis.

Even within this group, however, the evidence, regulatory status, appropriate patient population, and practical use vary substantially.

Gonadorelin

Gonadorelin is a synthetic form of GnRH, the hormone normally released by the hypothalamus to tell the pituitary to produce LH and FSH.

In patients with appropriate pituitary and testicular function, pulsatile GnRH therapy can restore downstream LH, FSH, and testosterone signaling. Studies of pulsatile gonadorelin therapy have commonly used administration approximately every 90 minutes to replicate physiologic signaling in patients with GnRH deficiency. [3] 

This makes the concept particularly relevant to certain forms of secondary, or hypogonadotropic, hypogonadism, in which the problem originates with inadequate signaling higher in the HPG axis rather than primary failure of the testes.

Pulsatile GnRH treatment has also been used to restore gonadotropin and testosterone production while supporting fertility in appropriately selected patients with hypothalamic causes of hypogonadism. [4] 

Gonadorelin is a prescription medication, but that does not mean every formulation, protocol, or use promoted online is FDA-approved. Its established approved uses in the United States have included diagnostic testing of hypothalamic-pituitary function and certain reproductive indications; use as a routine testosterone-optimization treatment in men should therefore be evaluated based on the specific product, indication, and clinical circumstances. [5] 

Monitoring may include total and free testosterone, LH, FSH, estradiol, symptoms, and fertility-related testing when relevant.

The key limitation is that gonadorelin depends on the rest of the pathway being capable of responding. If the pituitary or testes cannot respond adequately, stimulating the top of the axis may not produce the desired result.

HCG

Human chorionic gonadotropin, or HCG, is not technically a peptide in the narrowest sense; it is a glycoprotein hormone. However, it is frequently discussed alongside testosterone-related peptide therapies because it can directly stimulate endogenous testosterone production.

HCG acts similarly to LH. Instead of relying on the pituitary to produce an adequate LH signal, HCG binds to LH receptors in the testes and stimulates Leydig cells to produce testosterone.

This makes HCG particularly relevant when maintaining testicular function and fertility is a priority.

Exogenous testosterone can suppress LH and FSH signaling, reduce intratesticular testosterone, and decrease sperm production. [6] 

HCG has been used both as an alternative in selected hypogonadal men and alongside TRT in fertility-preserving strategies because it can help maintain intratesticular testosterone and testicular stimulation. [7] 

That does not mean HCG guarantees preserved fertility, and men actively trying to conceive may require a more comprehensive fertility evaluation or additional gonadotropin therapy. Treatment should be individualized based on hormone levels, semen parameters when appropriate, and reproductive goals.

HCG is available as a prescription medication. Because increased testicular testosterone production can also increase conversion to estradiol, monitoring commonly includes testosterone and estradiol, along with a broader safety panel appropriate to the patient and any concurrent testosterone therapy.

Kisspeptin

Kisspeptin sits even farther upstream than GnRH and is sometimes described as a master regulator of reproductive hormone signaling.

Rather than directly stimulating the testes, kisspeptin activates pathways in the hypothalamus that promote GnRH release. GnRH can then stimulate LH and FSH, which in turn signal the testes.

Human research has shown that kisspeptin can stimulate LH secretion and, in some experimental settings, increase testosterone. 

That makes kisspeptin scientifically interesting, particularly as researchers explore ways to influence endogenous reproductive hormone production without simply replacing testosterone.

But there is an important distinction between promising research and established treatment.

Kisspeptin remains investigational for testosterone optimization and should not be presented as an FDA-approved or routine therapy for low testosterone. The research supports continued investigation, not the assumption that commercially available “kisspeptin” products sold online are proven, regulated treatments.

For patients, that distinction should be a filter: compelling mechanism does not automatically equal clinically established therapy.

Peptides that support testosterone indirectly: GH secretagogues

One of the most persistent claims in peptide marketing is that growth hormone secretagogues “boost testosterone.”

That is not an accurate description of how they work.

Sermorelin, CJC-1295, and ipamorelin primarily affect the growth hormone axis. Depending on the compound, they can stimulate growth hormone release or influence growth hormone signaling, with downstream effects on IGF-1.

They do not directly stimulate the HPG axis in the way gonadorelin or HCG can.

Sermorelin

Sermorelin is an analogue of growth hormone-releasing hormone, or GHRH. It stimulates the pituitary to release growth hormone, which can subsequently increase IGF-1.

For some patients, addressing the growth hormone axis may be relevant to goals involving sleep, recovery, body composition, or age-related changes. But any improvement in those areas should not be confused with direct stimulation of testosterone production.

In other words, sermorelin may help address aspects of the physiologic environment in which hormonal health exists, but it is not a substitute for diagnosing and treating true testosterone deficiency.

Sermorelin is available through prescription compounding, although FDA approval of the former branded product is no longer active. Patients considering it should work with a qualified clinician and appropriately regulated pharmacy rather than purchasing products marketed for “research use.”

For a deeper look at its mechanism, potential benefits, limitations, and safety considerations, read our complete guide to sermorelin.

CJC-1295 and ipamorelin

CJC-1295 and ipamorelin are also commonly grouped with “testosterone peptides,” but neither should be described as directly raising testosterone.

CJC-1295 is a growth hormone-releasing hormone analogue, while ipamorelin is a growth hormone secretagogue that acts through the ghrelin receptor. Their primary target is growth hormone signaling, not the LH-testosterone pathway.

Neither CJC-1295 nor ipamorelin is FDA-approved for treating low testosterone, and products sold online as “research chemicals” should not be assumed to have pharmaceutical-grade purity, potency, sterility, or safety.

The FDA has specifically identified safety and quality concerns associated with compounded CJC-1295, including limited clinical data and reported serious adverse events. 

The evidence-forward position is straightforward: if your testosterone is low, a GH secretagogue should not be presented as though it directly corrects testosterone production. The first priority is determining why testosterone is low.

PT-141 (bremelanotide): libido, not testosterone

Bremelanotide, commonly known as PT-141 and sold under the brand name Vyleesi, belongs in a separate category.

It does not raise testosterone.

Bremelanotide acts primarily through melanocortin receptors in the central nervous system and is designed to influence pathways involved in sexual desire and arousal rather than the HPG axis.

Vyleesi is FDA-approved for acquired, generalized hypoactive sexual desire disorder in certain premenopausal women. 

It is not FDA-approved for male low libido or erectile dysfunction, so use in men is off-label. The FDA’s review specifically notes that the approved indication does not include men.

That distinction is particularly important because low libido and low testosterone are not interchangeable diagnoses.

A man can have low testosterone with normal sexual desire. He can also have normal testosterone and experience low libido due to medication effects, psychological factors, relationship factors, metabolic disease, sleep problems, vascular issues, or other causes.

Bremelanotide may be considered in selected cases involving sexual function, including alongside TRT or another hormone treatment when clinically appropriate. But it should never be described as a testosterone-raising peptide.

Peptides vs. TRT: the comparison behind the search

For many people searching for “testosterone peptides,” the real question is whether they can improve testosterone without taking testosterone itself.

The basic distinction is that HPG-axis therapies attempt to stimulate or substitute signals involved in your own testosterone production, while testosterone replacement therapy supplies exogenous testosterone directly.

That difference can have important implications for fertility. Exogenous testosterone suppresses the hormonal signals required for normal sperm production, while appropriately selected therapies that stimulate endogenous production may preserve more of the reproductive axis. [8] 

TRT, however, is an established treatment for appropriately diagnosed hypogonadism and can produce more direct and predictable increases in circulating testosterone than investigational peptide strategies. FDA-approved testosterone products are indicated for men with low testosterone associated with certain medical conditions. 

The best option therefore depends on the diagnosis, symptoms, fertility plans, lab pattern, and individual risk profile, not on whether one category is universally “better.”

For a deeper comparison of treatments designed to preserve endogenous hormone production (such as enclomiphene) versus testosterone replacement, see our guide to TRT vs. enclomiphene and our comprehensive TRT guide.

Why the right peptide depends on your labs

The most useful question is not “What is the best peptide for testosterone?”

It is “What do my labs say about why my testosterone is low?”

At minimum, an evaluation may include:

• Total testosterone
• Free testosterone
• LH
• FSH
• Estradiol
• Sex hormone-binding globulin, or SHBG

Depending on symptoms and medical history, a clinician may also evaluate prolactin, thyroid markers, complete blood count, metabolic markers, and other potential contributors.

LH and FSH are particularly important because they help distinguish primary from secondary hypogonadism. The Endocrine Society recommends measuring LH and FSH to differentiate testicular causes from hypothalamic or pituitary causes of low testosterone. 

If testosterone is low and LH and FSH are high

This pattern can suggest primary hypogonadism.

The brain and pituitary are already sending a strong signal, but the testes are not responding adequately. In that situation, adding more upstream stimulation may have limited value.

TRT or another treatment strategy may be more appropriate, depending on the diagnosis, symptoms, fertility goals, and clinical evaluation.

If testosterone is low and LH or FSH are low or inappropriately normal

This can suggest secondary hypogonadism.

The testes may retain the ability to produce testosterone, but the signal from the hypothalamus or pituitary may be inadequate. In selected patients, this is where therapies that stimulate or substitute parts of the HPG-axis signal may be considered.

The underlying cause still matters. Obesity, medications, elevated prolactin, pituitary disorders, severe illness, sleep problems, and other factors can contribute to secondary low testosterone and may require different treatment.

If testosterone is normal but libido is low

A testosterone-raising treatment may not address the actual problem.

This is where a broader evaluation becomes important. Bremelanotide may be relevant for selected patients because it targets sexual desire pathways rather than testosterone production, but male use is off-label and should be medically evaluated.

If the goal is recovery or body composition

A growth hormone secretagogue may be discussed separately from testosterone treatment, but it should not be prescribed or marketed under the assumption that increasing GH or IGF-1 automatically corrects low testosterone.

The right therapy should match the pathway that actually needs treatment.

This is the advantage of a lab-guided model. Concierge MD combines telehealth consultations, in-home lab testing where available, and ongoing clinical monitoring so treatment decisions can be based on physiology rather than online trends.

Monitoring should continue after treatment begins. HCG protocols may require follow-up testosterone and estradiol testing, particularly when combined with TRT. Gonadorelin-based approaches may require LH, FSH, and testosterone monitoring to determine whether the axis is responding.

And no matter which therapy you are considering, unregulated gray-market peptides deserve particular caution.

Products labeled “for research use only” may not be manufactured to the same standards as regulated prescription medications. The identity, concentration, sterility, and purity of an online product cannot be assumed simply because the label names a peptide that has appeared in legitimate research.

A promising study is not evidence that an unregulated vial purchased online contains the same compound, dose, or quality used in that study.

When to talk to a specialist

If you have symptoms of low testosterone, start with a comprehensive hormone evaluation rather than starting with a peptide.

Ask about testing total testosterone, free testosterone, LH, FSH, estradiol, and SHBG. Depending on your results and medical history, additional testing may be needed to determine whether the problem originates in the testes, pituitary, hypothalamus, metabolic health, medication use, or another factor.

If fertility matters now or may matter in the future, say so before beginning treatment. That information can materially change the treatment plan because exogenous testosterone can suppress sperm production. [9] 

It is also reasonable to ask direct questions about any peptide or hormone treatment being proposed:

• Does this treatment actually raise testosterone, or does it target another pathway?
• Is the medication FDA-approved for this use, prescribed off-label, compounded, or investigational?
• What evidence supports using it for my specific lab pattern?
• What labs will be monitored after I start?
• How could this treatment affect fertility?
• Where is the medication being sourced?

Those questions help separate a medically grounded treatment plan from peptide marketing.

Concierge MD’s model is designed to make that kind of evaluation more accessible through telehealth consultations, in-home lab testing where available, and ongoing medical oversight. The goal is not to match every symptom with the newest peptide. It is to understand what your body is actually doing, determine which pathway—if any—needs intervention, and choose a treatment whose benefits, limitations, and regulatory status are clear.

Schedule a free discovery call to start a conversation about if a peptide or hormone treatment is right for you.